BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28446883)

  • 1.
    Khroyan TV; Cippitelli A; Toll N; Lawson JA; Crossman W; Polgar WE; Toll L
    Front Psychiatry; 2017; 8():52. PubMed ID: 28446883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties.
    Cippitelli A; Zribi G; Toll L
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110599. PubMed ID: 35798174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
    Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
    Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
    Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
    Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET, an N-ethyl substituted aminothiazolomorphinan with κ agonist and μ agonist/antagonist activity.
    Sun JF; Wang YH; Chai JR; Li FY; Hang A; Lu G; Tao YM; Cheng Y; Chi ZQ; Neumeyer JL; Zhang A; Liu JG; Wang YJ
    Eur J Pharmacol; 2014 Oct; 740():455-63. PubMed ID: 24998879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence.
    Stevenson GW; Luginbuhl A; Dunbar C; LaVigne J; Dutra J; Atherton P; Bell B; Cone K; Giuvelis D; Polt R; Streicher JM; Bilsky EJ
    Pharmacol Biochem Behav; 2015 May; 132():49-55. PubMed ID: 25735493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
    Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
    Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Huang P; Ho CK; Cao D; Inan S; Rawls SM; Li M; Huang B; Pagare PP; Townsend EA; Poklis JL; Halquist MS; Banks M; Zhang Y; Liu-Chen LY
    J Pharmacol Exp Ther; 2024 Feb; 389(1):106-17. PubMed ID: 38409113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
    Lohmann AB; Welch SP
    Eur J Pharmacol; 1999 Dec; 385(2-3):119-27. PubMed ID: 10607867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects.
    Suzuki T; Nurrochmad A; Ozaki M; Khotib J; Nakamura A; Imai S; Shibasaki M; Yajima Y; Narita M
    Neuropharmacology; 2005 Dec; 49(8):1121-31. PubMed ID: 16095635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
    Jackson KJ; Carroll FI; Negus SS; Damaj MI
    Psychopharmacology (Berl); 2010 Jun; 210(2):285-94. PubMed ID: 20232057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ibogaine and noribogaine on the antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice.
    Bhargava HN; Cao YJ; Zhao GM
    Brain Res; 1997 Mar; 752(1-2):234-8. PubMed ID: 9106462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive Allosteric Modulation of CB
    Slivicki RA; Iyer V; Mali SS; Garai S; Thakur GA; Crystal JD; Hohmann AG
    Front Mol Neurosci; 2020; 13():54. PubMed ID: 32410959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.